How are you interpreting the early RASolute 302 trial findings (daraxonrasib) in metastatic PDAC?

Update 6/2/2026:

I think the early RASolute 302 signal is very promising and could be practice-changing, but I would still interpret it with some caution until we see the full dataset.

The reported improvement in overall survival is striking—approximately 13.2 months vs 6.7 months with chemotherapy, essentially a do...

Obviously, we must see the data and await the ASCO presentation eagerly.

But after years of gemcitabine plus “your drug here” trials (since first approved in 1996 based on an invented clinical endpoint), and seeing all those drugs fail, and after years of only improvement through chemotherapy triple...

Second-line therapy for KRAS-mutant metastatic PDAC currently follows the same framework as for all-comers, as no KRAS G12D–targeted agents are yet FDA-approved or included in the guidelines for PDAC. For patients with good PS (ECOG 0–1) after prior gemcitabine-based therapy, fluorouracil/leucovorin...

Now published on NEJM. HR for OS (all comers) = 0.45.

Game Changer! For RAS-mutated cancers of all sources.

Early RASolute 302 data strongly position daraxonrasib as a new standard of care for second-line mPDAC, though longer follow-up, resistance characterization, and exploration of combination strategies and first-line integration will be critical next steps.

This is the first targeted therapy to demonst...